Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Sanofi

Innogenetics N.v.

Université Lille 1 - Sciences Et Technologies

Université Lille 2 - Droit Et Santé

Universite Du Droit Et De La Santa-lille Ii

Université De Lille

Andre Delacourte

Nicolas Sergeant

Patricia Melnyk

Luc Buee

Eugeen Vanmechelen

Laurent Pradier

Veronique Blanchard-Bregeon

Stephane Burlet

Nicolas Lefur

Pierre Grognet

Marie Gompel

Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.

Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs. 

Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs

A monoclonal antibody which specifically binds to the N-terminal region of A&#x3b2;peptide, x being included from 11 to 42, and recognizes neither A&#x3b2;nor A&#x3b2;and which presents a high affinity with respect to A&#x3b2;peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A&#x3b2;.

Antibodies specific of the &#x3b2;-amyloid peptides and their uses as diagnostic agents or drugs

Growing community of inventors

Faches-Thumesnil, France

Andre Delacourte